A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT03565406 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
11
Enrollment
OTHER
Sponsor class

Stopped recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated

Conditions

Interventions

Sponsor

NYU Langone Health